Abstract
Motivation Time-to-event data in disease occurrence is often right-censored, requiring survival models for accurate predictions. While deep learning advancements have extended traditional Cox models, current approaches do not allow modeling on individual-level, large-scale genotype data. Scalable models integrating genetic and clinical data could enhance precision medicine and disease prediction.
Results We introduce EIRsurvival, a deep learning-based tool designed to perform time-to-event analyses on millions of SNPs from large, individual-level cohorts. We applied EIRsurvival to predict time-to-diagnosis for eight diseases in the UK Biobank, utilizing 1.13M genetic variants from 487,027 individuals. The model achieved C-indices between 0.55 and 0.68 using genetic data alone, with performance improving to 0.67–0.96 when integrating multi-omics data. Automated feature attribution analysis confirmed biologically relevant feature associations.
Availability and Implementation EIRsurvival is available through the eir-dl framework at github.com/arnor-sigurdsson/EIR, with documentation accessible at eir.readthedocs.io/en/latest/other/01_survival_genotypes.html. The tool is optimized for GPU acceleration, facilitating efficient training on high-dimensional data.
Contact Simon Rasmussen (srasmuss{at}sund.ku.dk)
Supplementary Information Supplementary information is available online.
Competing Interest Statement
S.R. is the founder and owner of BioAI and has performed consulting for Sidera Bio ApS. The remaining authors declare no competing interests.
Funding Statement
S.R., J.F.G., and T.H. were supported by the Novo Nordisk Foundation (NNF23SA0084103). J.F.G. was supported by a research grant from the Danish Cardiovascular Academy, which is funded by the Novo Nordisk Foundation, grant number NNF20SA0067242 and The Danish Heart Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present analyses were conducted under UK Biobank data application number 32683. The UK Biobank received ethical approval from the North West - Haydock Research Ethics Committee (21/NW/0157).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
UK Biobank genotype, proteomics and covariate data is available to approved researchers through the UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access).
